SCHEMBL30294526

SCHEMBL30294526

COc1ccc(NC(=O)c2cc(C(F)(F)F)ccc2Nc2cc(F)c(F)cc2C)c(C)n1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SORT1 Q99523 6/20 0.46
▸ HPGD P15428 3/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ NTRK1 P04629 1/20 0.43
▸ NTRK2 Q16620 1/20 0.43
▸ DHODH Q02127 1/20 0.42
▸ TAS2R14 Q9NYV8 1/20 0.40
▸ SCN9A Q15858 2/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ LCLAT1 Q6UWP7 1/20 0.39
▸ SCN8A Q9UQD0 1/20 0.39
▸ SCN10A Q9Y5Y9 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPK3 P27361 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22853186 1.00 SORT1 (0.46) SORT1HPGDKDM4ENTRK1NTRK2
SCHEMBL29382977 0.90 SCN8A (0.47) SORT1HPGDKDM4ENTRK1NTRK2
SCHEMBL22853425 0.90 SCN8A (0.47) SORT1HPGDKDM4ENTRK1NTRK2
SCHEMBL30294376 0.88 SORT1 (0.46) SORT1HPGDKDM4ENTRK1NTRK2
SCHEMBL22852910 0.88 SORT1 (0.46) SORT1HPGDKDM4ENTRK1NTRK2
SCHEMBL30294361 0.88 SCN8A (0.47) SORT1KDM4EDHODHRXFP1SCN8A
SCHEMBL22853243 0.88 SCN8A (0.47) SORT1KDM4EDHODHRXFP1SCN8A
SCHEMBL22853430 0.87 SORT1 (0.45) SORT1HPGDKDM4ENTRK1NTRK2
SCHEMBL30294432 0.87 SORT1 (0.45) SORT1HPGDKDM4ENTRK1NTRK2
SCHEMBL22853181 0.87 SORT1 (0.52) SORT1HPGDKDM4ENTRK1NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B SORT1 3573/4885HPGD 3374/4885KDM4E 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback